Treatment Study for Patients with Acute Myeloid Leukemia
To compare event free survival (EFS) and overall survival (OS) in patients with de nova acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD+mutations who are randomized to standard therapy versus bortezomib/standard combination therapy.
In order to participate you must meet the following criteria:
- Are less that 30 years of age at the time of study enrollment.
- Have been newly diagnosed with de novo acute myelogenous leukemia.
This is a partial list of elgibility requirements.